Dupilumab improves eosinophilic esophagitis outcomes through 52 weeks

Weekly subcutaneous doses of dupilumab improved histologic outcomes and alleviated symptoms for adults and adolescents with eosinophilic esophagitis, according to a study published in The New England Journal of Medicine.“The surprising result was that clinical symptom improvement only occurred with weekly dosing even though all other endpoints improved with every-other-week dosing,” Marc E. Rothenberg, MD, PhD, director of the division of allergy and immunology at Cincinnati Children’s Hospital and a Healio Allergy/Asthma Peer Perspective Board Member, told Healio, addingRead More